Medicines List

Select category
  • Description

    Bacteripime belongs to a group of antibiotics called ‘cephalosporins’ and it’s an antibiotic given as an infusion (a drip) or as a slow injection.

    The mechanism of action of cefepime is based on inhibition of bacterial cell wall synthesis (in the growth phase), due to inhibition of penicillin-binding proteins (PBPs) e.g. transpeptidases. This results in a bactericidal action.

    Indications

    Bacteripime is effective against certain types of bacteria that are sensitive to the active substance cefepime, that are resistant to other antibiotics:

    • Infections of the lower respiratory tract infections, including pneumonia and bronchitis;
    • Urinary tract infections as complications, including pyelonephritis and uncomplicated infections;
    • Intra-abdominal infections, including peritonitis and gallbladder infection
    • Gynecological infections;
    • Septicemia (blood poisoning) and bacteremia (the presence of bacteria in the circulating blood);
    • Empirical treatment of febrile neutropenia (reduced the neutrophil leucocytes in peripheral blood).

    Children

    Bacteripim is indicated for the treatment of pediatric infections listed below caused by susceptible bacteria:

    • Pneumonia
    • Urinary tract infections as complications including pyelonephritis and uncomplicated infections;
    • Skin infections and infections of the layers beneath the skin,
    • Septicemia;
    • Empirical treatment of febrile neutropeniaя;
    • Bacterial meningitis.

    Subject to medical prescription

    Pharmaceutical form: Bacteripime 1 g powder for solution for injection/infusion x 1 vial

    ATC code: J01DE01

    Bacteripim_3d
  • Description

    The active substance of LanzAcid is  lansoprazole. It belongs to a group of medicines called proton pump inhibitors.

    Lansoprazole works by lowering the amount of acid in your stomach.

    Indications

    Treatment of duodenal and gastric ulcer

    •  treatment of reflux oesophagitis;

    • treatment of essential hypertension in adults;

    • eradication of Helicobacter pylori (H. pylori) concurrently given with appropriate antibiotic therapy for treatment of H.pylori-associated ulcers

    • Zollinger-Ellison syndrome

    • treatment of NSAID-associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment

    • prophylaxis of NSAID-associated gastric ulcers and duodenal ulcers in patients at risk  requiring continued therapy

    • symptomatic gastroesophageal reflux disease

    Subject to medical prescription

    Pharmaceutical form: LanzAcid 30 mg gastro-resistant capsules, hard x30 capsules

    NHIF code:AF496

    ICD:K20; K25.7; K26.7

    АТС: A02BC03

    LanzAcid
  • Desctription

    Telsart belongs to a class of medicines known as angiotensin II receptor antagonists. Angiotensin II is a substance produced in your body which causes your blood   vessels to narrow, thus increasing your blood pressure. Telsart blocks the effect of angiotensin  II so that the      blood vessels relax, and your blood pressure is lowered.

    Telmisartan is an orally active and specific angiotensin II receptor (type AT1) antagonist. Telmisartan displaces angiotensin II with very high affinity from its binding site at the AT1 receptor subtype, which is responsible for the known actions of angiotensin II.

    Indications

    Treatment of essential hypertension in adults.

    Subject to medical prescription

    Pharmaceutical form: Telsrt 80 mg tablets x28; x30 tablets

    NHIF code: CG201

    ICD: I10, I11.0, I11.9, I12.0, I12.9, I13.0, I13.1, I13.2

    АТС: С09СА07

    Telmisartan
  • Desctription

    Pulmohyperta tablets contains bosentan and belong to a group of medicines called “endothelin receptor antagonist”.

    Bosentan is a dual endothelin receptor antagonist (ERA) with affinity for both endothelin A and B (ETA and ETB) receptors. Bosentan decreases both pulmonary and systemic vascular resistance resulting in increased cardiac output without increasing heart rate.

    Indications

    Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:
    • Primary (idiopathic and heritable) pulmonary arterial hypertension
    • Pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease
    • Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s physiology
    Some improvements have also been shown in patients with pulmonary arterial hypertension WHO functional class II.

    Subject to medical prescription

    Pharmaceutical form: Pulmohyperta 62,5 mg film-coated tablets x 56 tablets

    NHIF code:

    ICD: I27.0; M34.0, M34.1, M34.2, M34.8;  Q21.8

    Pharmaceutical form: Pulmohyperta 125 mg film-coated tablets x 56 tablets

    NHIF code: CG192

    ICD: I27.0; M34.0, M34.1, M34.2, M34.8;  Q21.8

    АТС: C02KX01

    Pulmo